Ophthotech Reports Fovista Phase 2b Independent Analysis - Quick Facts

(RTTNews) - Ophthotech Corp. (OPHT) announced that a subgroup analysis assessing the development and progression of sub-retinal fibrosis in the company's Phase 2b study, which compares Fovista (1.5mg) combination therapy with Lucentis (0.5mg) versus Lucentis (0.5mg) monotherapy would be presented at the American Academy of Ophthalmology 2014 Annual Meeting in Chicago, Illinois.

Sub-retinal fibrosis is a major cause of visual loss in wet age-related macular degeneration or AMD patients treated with the current standard of care, anti-VEGF monotherapy, as per third party studies.

David Guyer, M.D., Chief Executive and Chairman of the Board of Ophthotech, noted: "The occurrence of sub-retinal fibrosis is considered to be the best clinical predictor of poor visual outcome in wet AMD treated patients. Thus, we believe that the potential for inhibiting formation or progression of sub-retinal fibrosis with Fovista® combination therapy holds great promise for treating an unmet medical need for wet AMD patients. We are currently enrolling patients in the initial trial of our anti-fibrosis program to confirm these findings."